Stock Lookup:   

The StockSpiker Daily 100 and Weekly 100 Covers The Biggest Movers In The Market    Click For The Latest Report

 
Orexigen Therapeutics, Inc. (OREX)

Last Traded At:  $5.44     + $0.85
Volume:   8,329,680
Price/Earnings:   $0.00
Earnings Per Share:   ($1.20)
52 Week High:   $10.83
52 Week Low:   $3.81
StockSpiker Coverage & Performance
This stock has been covered by StockSpiker on the following dates. In addition, the percentage change from the coverage date and today's price is shown.
Coverage Coverage
Date
Gain Since Then
Top 100 Weekly Gainers 7/30/2010: 4%
7/30/2010: 4%
Top 100 Weekly Gainers 7/2/2010: 19%
5/1/2009: 47%
Top 100 Weekly Losers 5/21/2010: 3%
1/8/2010: -24%
Top 100 Weekly Losers 4/24/2009: 62%
4/17/2009: 54%
Top 100 Daily Gainers 9/2/2010: 0%
8/2/2010: -8%
Top 100 Daily Gainers 7/30/2010: 4%
7/30/2010: 4%
Top 100 Daily Gainers 7/13/2010: 8%
6/28/2010: 10%
Top 100 Daily Gainers 2/2/2010: -31%
12/14/2009: -42%
Top 100 Daily Gainers 7/3/2009: -4%
7/2/2009: -4%
Top 100 Daily Gainers 6/2/2009: 20%
5/8/2009: 49%
Top 100 Daily Losers 8/4/2010: -1%
7/16/2010: 17%
Top 100 Daily Losers 6/29/2010: 20%
6/17/2010: 20%
Top 100 Daily Losers 5/21/2010: 3%
2/4/2010: -14%
Top 100 Daily Losers 7/23/2009: -44%
Add OREX Email Alerts
Get an email or text alert anytime a stock appears on our Daily or Weekly 100 Report!
Email:
Ticker(s):  
About Orexigen Therapeutics, Inc.
Orexigentm Therapeutics, Inc. ("Orexigen", "we", "our" and "us") is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system, or CNS, disorders, including obesity. Our lead product candidates targeted for obesity are Contravetm, which is in Phase III clinical trials, and Empatictm, which is in the later stages of Phase II clinical development. Each of these product candidates is a combination of generic drugs, which we have systematically screened for synergistic CNS activity. We seek to combine chemical entities that, individually, have already received regulatory approval and have been commercialized previously, into new product candidates that we believe address unmet medical needs and are patentable. We are testing these combinations in an effort to demonstrate adequate efficacy and safety for potential regulatory approval.

News For Orexigen Therapeutics, Inc.
5/17/2010 8:26:42 PM The Pharma Initiative: Three Stock Picks (at Seeking Alpha)
5/17/2010 8:15:00 PM [$$] Rob's Wrap: S&P 500, OREX, VCLK, ALSK (at TheStreet.com)
5/11/2010 2:51:08 AM Orexigen Therapeutics, Inc. Q1 2010 Earnings Call Transcript (at Seeking Alpha)
5/10/2010 9:00:00 PM Orexigen Therapeutics, Inc. Earnings Call scheduled for 5:00 pm ET today (CCBN)
5/10/2010 8:19:45 PM OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a (EDGAR Online)
5/10/2010 8:01:00 PM OREXIGEN(R) Therapeutics Reports First Quarter 2010 Financial and Operational Results (PR Newswire)
5/10/2010 12:00:00 PM Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference (PR Newswire)
5/10/2010 11:07:23 AM Q1 2010 Orexigen Therapeutics, Inc. Earnings Release - After Market Close (CCBN)
5/6/2010 12:00:00 PM Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010 (PR Newswire)
4/22/2010 3:04:27 PM A Big Upgrade for Arena Pharmaceuticals (at Motley Fool)

About Us |  FAQs |  Privacy Policy |  Terms & Conditions |  Contact Us Copyright © 2010 STOCK SPIKER LLC All Rights Reserved  

    

This website is intended to provide information only. If you are seeking advice on any matters relating to information on this website, you should - where appropriate - contact your broker or investment manager directly with your specific questions or seek advice from qualified Professional Financial advisor.

Whether you are a technical daytrader, or a long term fundamental investor, the StockSpiker gives you investment ideas based on the most relevant recent price history of stocks. Here are some recent movers that we have reported on:


Stock Lookup: